Citi Upgrades Merus N.V. (MRUS) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
Go back to Citi Upgrades Merus N.V. (MRUS) to Buy
December 21, 2016 11:50 AM EST
Wedbush analyst David Nierengarten raised his price target on Outperform-rated Merus N.V. (NASDAQ: MRUS) to $32.00 (from $16.00) after the company and Incyte announced a collaboration to develop up to eleven bispecific antibody research programs using MRUSs Biclonics platform, including two of MRUSs current preclinical... More
December 21, 2016 8:15 AM EST
Merus N.V. (NASDAQ: MRUS) surges 51% in pre-open trade after the company and Incyte Corporation (NASDAQ: INCY) entered into a global,... More
December 21, 2016 7:02 AM EST
Incyte Corporation (NASDAQ: INCY) and Merus N.V. (NASDAQ: MRUS) announced today that they have entered into a global, strategic collaboration agreement focused on the research, discovery and development of bispecific antibodies utilizing Merus proprietary Biclonics® technology platform. The Collaboration and License Agreement grants Incyte the exclusive rights for up to eleven bispecific antibody research programs, including two of Merus current preclinical immuno-oncology discovery programs.
Biclonics® retain the IgG format of antibodies that are produced naturally by the immune system and, by binding to two targets, enable multiple modes of... More
